Haematology A
FLIPI — Follicular Lymphoma International Prognostic Index
Predicts overall survival in follicular lymphoma. Based on 5 adverse factors.
Score interpretation
Low Risk 0–1
Low risk. 10-year OS ~71%.
→ Watch and wait or rituximab monotherapy. Consider clinical trial enrolment.
Intermediate Risk 2
Intermediate risk. 10-year OS ~51%.
→ Chemoimmunotherapy (R-CHOP, R-bendamustine) as per ESMO/NICE guidelines. Maintenance rituximab.
High Risk 3–5
High risk. 10-year OS ~36%.
→ Intensive chemoimmunotherapy. Consider clinical trial. Haematology specialist centre referral.
Interpretation bands for the FLIPI. Apply clinical judgement and local guidance.
References
- Solal-Celigny P et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Fong Clinical Risk Score for CRC Liver Metastases · Cancer Prognosis
- CLL-IPI (International Prognostic Index for CLL) · Cancer Prognosis
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- WPSS — WHO Prognostic Scoring System for MDS · Cancer Prognosis
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
Drugs
- Obinutuzumab · Anti-CD20 Monoclonal Antibody — CLL / Follicular Lymphoma
- Idelalisib · PI3Kδ Inhibitor — CLL / Follicular Lymphoma
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.